Public Comment for Screening for Lipid Disorders in Children and Adolescents

Family Heart Foundation Public Comment for Screening for Lipid Disorders in Children and Adolescents

No Comments

A Response to the US Preventive Service Task Force

On January 24, 2023, the US Preventive Services Task Force (USPSTF) released their draft recommendation based on evidence of the benefits and harms of screening for lipid disorders, including familial hypercholesterolemia (FH), in children and … Read More →


Highlights from AHA 2022

FDA Approves Inclisiran

A Global Call to Action for FH

A Global Call to Action – Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia

No Comments

Healthcare systems around the world have failed to rescue individuals born with Familial Hypercholesterolemia (FH), even though we have had life-saving therapies for the last 34 years. Without the societal commitment to screen, diagnose, and manage FH, the opportunity to prevent heart disease and … Read More →


News Alert - FDA Approves Evinacumab

ICER Virtual Public Meeting

ICER Report on Treatments for High Cholesterol – Family Heart Foundation to Comment at Public Meeting February 5

No Comments

The Institute for Clinical and Economic Review (ICER) – an organization that produces reports that analyze the cost effectiveness of drugs and other medical services – has highlighted the improved cost-effectiveness of high cholesterol treatments inclisiran and bempedoic acid in patients who have … Read More →


FDA Listening Session on HoFH

photo of people raising hand to advocate

First Iraqi Advocacy Group

Capitol Hill